ArticleSkeletal radiology2007
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid.
Article in Skeletal radiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.European radiology · 2009Trial
- Diagnostic performance of dual-layer spectral CT Radiomics and deep learning for differentiating osteoblastic bone metastases from bone islands.European journal of radiology open · 2025Article
- Value of CT-based radiomics in evaluating the response of bone metastases to systemic drug therapy in breast cancer patients.Thoracic cancer · 2024Article
- Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.BMC cancer · 2023Review
- Computed tomography density changes of bone metastases after concomitant denosumab.Skeletal radiology · 2023Article
- Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.BMC pulmonary medicine · 2022Observational
- Computed tomography bone density variations in oncological patients undergoing antiresorptive medication.Medicina oral, patologia oral y cirugia bucal · 2022Article
- Article
- Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.Skeletal radiology · 2017Article
- VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.Fukushima journal of medical science · 2015Article
- Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy.The British journal of radiology · 2012Article
- Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.Journal of bone oncology · 2012Article
- Differentiation of normal and neoplastic bone tissue in dynamic gadolinium-enhanced magnetic resonance imaging: validation of a semiautomated technique.La Radiologia medica · 2010Article
- Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2010Review
- Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.Clinical & experimental metastasis · 2009Article
- Types of bone metastases in women with breast cancer undergoing systemic treatments.La Radiologia medica · 2008Article
- Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study.Journal of Indian Prosthodontic SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months. PATIENTS AND
methodsTwenty-three consecutive patients presented with bone metastases and underwent therapy with zoledronic acid from December 2004. All patients underwent CT of the chest, abdomen, and pelvis. Bone density, measured in Hounsfield units (HU), was determined by segmenting lesions in the same anatomical area of the metastasis sites on the axial images of the sequential series of CT examinations. The effects of zoledronic acid were evaluated by calculating absolute and relative increases in bone density.
resultsThe patients presented with multiple metastases in 65% of the cases. When compared with the baseline, all groups demonstrated a significant increase in bone density, which significantly (p < 0.01) correlated with the number of zoledronic acid administrations. There was increased bone density of at least 100% in 57%, and an increase of at least 50% in 87% of the patients. This increase was significant in both lytic and sclerotic metastases after 3 months of therapy. No significant bone density difference was found in normal-appearing bone.
conclusionBone density measured by CT increases at metastatic sites after zoledronic acid treatment, regardless of the type of metastasis, in contrast to apparently normal bone.
Indexed as
Identifiers
17912514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.